Batoclimab
Phase 3FcRn antibody whose partner reported thyroid eye disease Phase 3 results and is focusing on its successor molecule.
FROM PUBLIC EVENTS · 2026-11-15
Pipeline reshaping After its partner reported Phase 3 results for the first molecule, development is shifting to the successor.
Roles often seen at this stageBD & licensing · Clinical & PV · Research & development
A biopharmaceutical company that has licensed autoimmune antibody candidates to overseas partners and sells medicines in Korea.
FcRn antibody whose partner reported thyroid eye disease Phase 3 results and is focusing on its successor molecule.
Next-generation FcRn antibody whose development the partner is accelerating.
The partner reported results of two Phase 3 trials of batoclimab in thyroid eye disease.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.